RxDoctor Payments Data

David Wu, MD

Pulmonary Disease · Huntington Woods, MINPI 1740236652

Payments from drug & device makers

$13,192in general payments, 2019–2025

Across 711 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • Boehringer Ingelheim$2K
  • AstraZeneca$2K
  • Mylan Specialty L.p.$849
  • Grifols USA, LLC$714
  • Sanofi$559
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$13,11399%
  • Education$791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,192 in reported general payments places this provider in the 80th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$185,491
Medicare patients
502
Services billed
2,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate12$261,040
Trelegy ElliptaFluticasone/Umeclidin/Vilanter159$139,239
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr90$50,926
Stiolto RespimatTiotropium Br/Olodaterol Hcl62$46,141
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$35,835
Spiriva RespimatTiotropium Bromide43$29,899
Breo ElliptaFluticasone/Vilanterol54$29,222
Pirfenidone16$20,557
SymbicortBudesonide/Formoterol Fumarate39$14,115
Albuterol Sulfate HfaAlbuterol Sulfate221$7,069
Fluticasone-VilanterolFluticasone/Vilanterol13$4,661
Advair HfaFluticasone Propion/Salmeterol14$4,304
Incruse ElliptaUmeclidinium Bromide11$4,010
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$3,133
Ventolin HfaAlbuterol Sulfate38$2,631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$2,054$337,080117 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$2,664$226,017327 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,583$49,95186 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Huntington Woods

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →